Poster Session B
Periodic fever syndromes, autoinflammatory diseases, Still’s disease and MAS/HLH
Laura Bucci, MD (she/her/hers)
Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen
Erlangen, Bayern, Germany
No financial relationships with ineligible companies to disclose
Treatment with bispecific T-cell engagers had a favorable safety profile in 12 patients with refractory autoimmune disease. Hence, targeting CD19 or BCMA with T cell engagers appears feasible in autoimmune disease and warrants further clinical development.
References:
1. Bucci L, Hagen M, Rothe T, et al. Bispecific T cell engager therapy for refractory rheumatoid arthritis. Nat Med 2024. DOI: 10.1038/s41591-024-02964-1.
2. Moreau P, Garfall AL, van de Donk N, et al. Teclistamab in Relapsed or Refractory Multiple Myeloma. N Engl J Med 2022;387(6):495-505. DOI: 10.1056/NEJMoa2203478.
Table 1: Demographics und safety data of patients treated with Blinatumomab or Teclistamab. HS=Herpes simplex, UTI=Urinary tract infection, GE=Gastroenteritis, CUT=cutaneous infection, URI=upper respiratory infection.
M. Hagen: None; L. Bucci: None; S. Boeltz: None; D. Noethling: None; T. Rothe: None; M. Raimondo: None; C. Tur: None; A. Wirsching: None; J. Wacker: None; A. Bozec: None; G. Schett: Bristol-Myers Squibb(BMS), 6, Cabaletta, 6, Janssen, 6, Kyverna Therapeutics, 6, Novartis, 6; R. Grieshaber-Bouyer: None.